P/E ratio for Pharmanutra (PHN.MI)
P/E ratio as of April 2025 (TTM): 34.8
According to Pharmanutra's latest financial reports and stock price the company's current price-to-earnings ratio (TTM) is 34.7722. At the end of 2023 the company had a P/E ratio of 42.4.
P/E ratio history for Pharmanutra from 2023 to 2024
PE ratio at the end of each year
| Year | P/E ratio | Change |
|---|---|---|
| 2023 | 42.4 | 6.19% |
| 2022 | 39.9 | -24.79% |
| 2021 | 53.1 | 104.77% |
| 2020 | 25.9 | -3.59% |
| 2019 | 26.9 | 54.38% |
| 2018 | 17.4 | -14.54% |
| 2017 | 20.4 |
How to read a P/E ratio?
The Price/Earnings ratio measures the relationship between a company's stock price and its earnings per share. A low but positive P/E ratio stands for a company that is generating high earnings compared to its current valuation and might be undervalued. A company with a high negative (near 0) P/E ratio stands for a company that is generating heavy losses compared to its current valuation.
Companies with a P/E ratio over 30 or a negative one are generaly seen as "growth stocks" meaning that investors typically expect the company to grow or to become profitable in the future.
Companies with a positive P/E ratio bellow 10 are generally seen as "value stocks" meaning that the company is already very profitable and unlikely to strong growth in the future.